Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Four Week Study of the Efficacy and Safety of Four Doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of Aplindore MR Tablets vs. Placebo in Idiopathic Restless Legs Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aplindore (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Neurogen Corporation
- 25 Sep 2014 New trial record